CORRECTION

Correction to: Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons

Chakrapani Balijepalli · Rohan Shirali · Prashanth Kandaswamy ·
Anastasia Ustyugova · Egon Pfarr · Søren S. Lund · Eric Druyts

Published online: December 5, 2018
© The Author(s) 2018

Correction to: Diabetes Ther (2018) 9:1491–1500
<https://doi.org/10.1007/s13300-018-0456-7>

In the original publication, Figure 3 was incorrectly published. The authors have updated figure 3 and the corrected Fig. 3 is given below.

The original article can be found online at <https://doi.org/10.1007/s13300-018-0456-7>.

C. Balijepalli (✉) · R. Shirali · E. Druyts
Precision Health Economics, Vancouver, BC,
Canada
e-mail: chakrapani.balijepalli@precisionxtract.com

P. Kandaswamy · A. Ustyugova · E. Pfarr · S. S. Lund
Boehringer Ingelheim GmbH, Ingelheim, Germany

Fig. 3 Plots presenting indirect comparisons of empagliflozin versus other glucose-lowering drugs

Open Access. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-

commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.